These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. A comparative study of antipyrine pharmacokinetics in saliva and plasma using a colourimetric method of antipyrine analysis. Harman AE; Priestly BG; Frewin DB Clin Exp Pharmacol Physiol; 1977; 4(6):593-6. PubMed ID: 589875 [TBL] [Abstract][Full Text] [Related]
5. Antipyrine kinetics in liver disease and liver transplantation. Mehta MU; Venkataramanan R; Burckart GJ; Ptachcinski RJ; Yang SL; Gray JA; Van Thiel DH; Starzl TE Clin Pharmacol Ther; 1986 Apr; 39(4):372-7. PubMed ID: 3514052 [TBL] [Abstract][Full Text] [Related]
6. Salivary antipyrine half-life: a useful measure of hepatic drug metabolism. Brooks PM; Bell MA; Burns H Br J Clin Pharmacol; 1976 Oct; 3(5):945-6. PubMed ID: 973995 [No Abstract] [Full Text] [Related]
8. Effect of a non-steroid anti-inflammatory agent on the drug metabolizing activity of the human liver. Gachályi B; Vas A; Káldor A Int J Clin Pharmacol Ther Toxicol; 1984 Jul; 22(7):353-4. PubMed ID: 6469424 [TBL] [Abstract][Full Text] [Related]
9. Enhanced antipyrine metabolism in cigarette smokers in Indian population. Uppal R; Garg SK; Sharma PR; Nair CR; Chaudhury RR Int J Clin Pharmacol Ther Toxicol; 1980 Jun; 18(6):269-71. PubMed ID: 7450928 [TBL] [Abstract][Full Text] [Related]
10. Antipyrine repeatability and comparison of the powder and capsule formulations. Edeki T; Turner P Int J Clin Pharmacol Ther; 1995 Feb; 33(2):70-5. PubMed ID: 7757313 [TBL] [Abstract][Full Text] [Related]
11. Influence of mild thyroid dysfunction on antipyrine clearance and metabolite formation in man. Teunissen MW; van der Veen EA; Doodeman PJ; Breimer DD Eur J Clin Pharmacol; 1984; 27(1):99-103. PubMed ID: 6489432 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and metabolism of antipyrine (phenazone) after intravenous and oral administration. Eichelbaum M; Ochs HR; Roberts G; Somogyi A Arzneimittelforschung; 1982; 32(5):575-8. PubMed ID: 7201837 [TBL] [Abstract][Full Text] [Related]
15. [Determination of nonmetabolized antipyrine in human urine]. Gozhenko AI; Dolomatov SI; Mosklaenko TIa; Iakimenko LV; Ambrosiĭchuk EV; Dolomatova EA Eksp Klin Farmakol; 2004; 67(3):59-60. PubMed ID: 15341072 [TBL] [Abstract][Full Text] [Related]
16. [Oxidative hepatic metabolism in chronic alcoholics during the acute abstinence period: evaluation with antipyrine elimination]. Soto Alvarez J; Alsar Ortiz MJ Rev Clin Esp; 1993 Jun; 193(2):60-3. PubMed ID: 8341815 [TBL] [Abstract][Full Text] [Related]
17. Metabolic disposal of antipyrine and lipid peroxidation indices in volunteers jointly exposed to industrial organic solvents and ethanol. Wiśniewska-Knypl J; Jajte J; Wrońska-Nofer T; Kostrzewski P Pol J Occup Med Environ Health; 1993; 6(2):157-67. PubMed ID: 8219907 [TBL] [Abstract][Full Text] [Related]
18. Antipyrine half-life in hyperthyroidism. Obel AO; Ng'ang'a J; Gitau W East Afr Med J; 1981 Apr; 58(4):258-62. PubMed ID: 7261979 [No Abstract] [Full Text] [Related]
19. Antipyrine kinetics in Nigerian women in chronic renal failure. Iyun AO; Tucker GT Afr J Med Med Sci; 1982 Mar; 11(1):7-9. PubMed ID: 6291357 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of sulfamerazine and antipyrine in neonatal and young lambs. De Backer P; Belpaire FM; Bogaert MG; Debackere M Am J Vet Res; 1982 Oct; 43(10):1744-51. PubMed ID: 7149373 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]